B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
VSTM
VerastemCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.75
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-09
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.6
Score
AI commentary
Recent news tone is moderately constructive after the Q2 update, driven by commercial revenue, funding, and the October clinical-data catalyst. Social coverage, options data, short interest, employee sentiment, and post-print analyst revisions are unavailable; missing data is not treated as positive evidence.
RankAlpha Sentiment Codex - 2026-08-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-11-07eventVS-7375 October clinical updateHigh impact
The company reported first patients dosed in three Phase 2 registration-directed studies across pancreatic, non-small-cell lung, and colorectal cancers, with additional clinical data expected in October and enrollment targeted for completion by year-end. [#SEC-8K-2026-08-06]
2026-12-31eventCommercial uptake and LGSOC self-sufficiencyHigh impact
Q2 AVMAPKI FAKZYNJA CO-PACK net product revenue was $25.1 million, and management expects the LGSOC business to become self-sustaining by the end of 2026. [#SEC-8K-2026-08-06]
2027-08-09catalystExtended non-dilutive funding runwayHigh impact
The company reported up to $75 million of royalty financing, $136.4 million of quarter-end cash and pro forma cash of $201.4 million, with runway expected into the second half of 2027. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-09 • Updated nightlySource: Internal modelMethodology